Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05027139 · ClinicalTrials.gov registry record · Phase 1
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
A Phase 1 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT05027139 is a Phase 1 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT05027139, a Phase 1 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study is being done to find out if zanidatamab when given with evorpacept (ALX148) is safe and can treat patients with advanced (locally advanced \[inoperable\] and/or metastatic) human epidermal growth factor receptor 2 (HER2)-expressing cancer.
Interventions
- DRUG Zanidatamab
- DRUG Evorpacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-09-15 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05027139
The ClinicalTrials.gov registry entry for NCT05027139 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zanidatamab is the first listed.
NCT05027139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05027139 about?
NCT05027139 is a clinical study titled "A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer". This study is being done to find out if zanidatamab when given with evorpacept (ALX148) is safe and can treat patients with advanced (locally advanced \[inoperable\] and/or metastatic) human epidermal growth factor receptor 2 (HER2)-expressing cancer.
What is the current status of trial NCT05027139?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2021-09-15. Estimated completion is 2025-09-30.
What interventions are being tested in trial NCT05027139?
The interventions under investigation include: Zanidatamab (DRUG), Evorpacept (DRUG).
Who is sponsoring clinical trial NCT05027139?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.